Form 4: Day One Biopharmaceuticals COO, CFO, and Secretary Charles N. York II Reports Stock Transactions

Charles N. York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, reported the acquisition of shares through RSU vesting and subsequent sale of shares to cover tax obligations.

Summary

• Charles N. York II, the COO, CFO, and Secretary of Day One Biopharmaceuticals, has reported several transactions involving the company's stock.
• On November 15, 2024, York acquired a total of 10,250 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• These RSUs vested in three tranches: 1,375, 2,250, and 6,625 shares.
• On November 18, 2024, York sold 2,602 shares of common stock at a weighted average price of $13.2102 per share.
• The sale was solely to cover tax liabilities associated with the vesting of the RSUs.
• Following these transactions, York beneficially owns 240,133 shares of Day One Biopharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The stock acquisition through RSU vesting is positive, but the subsequent sale, even for tax purposes, can be viewed as slightly negative. Overall, it's a routine transaction.

Positives

• The vesting of RSUs indicates that performance milestones were likely met.
• The sale of shares was explicitly for tax obligations, not necessarily a negative sentiment on the company's future.

Negatives

• The sale of shares, even for tax purposes, could be interpreted as a slight negative signal by some investors.

Risks

• Executive stock sales, even for tax purposes, can sometimes create short-term price volatility.
• The market may react negatively to any insider selling, regardless of the reason.

Industry Context

This is a routine filing for insider transactions and is common in the biotechnology industry where stock-based compensation is prevalent.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, particularly in the biotech sector where equity compensation is common.
• The vesting and subsequent sale of shares for tax purposes is a typical pattern observed across various companies.
• The volume of shares traded is relatively small compared to the overall market capitalization of Day One Biopharmaceuticals.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they involve a relatively small number of shares.
• The sale of shares could cause a slight dip in the share price in the short term.

Key Dates

Keywords

insider trading, Form 4, stock transaction, RSU, Day One Biopharmaceuticals, DAWN, executive compensation, Charles N. York II